140 related articles for article (PubMed ID: 15642997)
1. Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.
Tadesse A; Shannon EJ
Clin Diagn Lab Immunol; 2005 Jan; 12(1):130-4. PubMed ID: 15642997
[TBL] [Abstract][Full Text] [Related]
2. In vitro thalidomide does not interfere with the activation of complement by M. leprae.
Shannon EJ; Sandoval FG; Morales MJ
J Drugs Dermatol; 2011 Mar; 10(3):274-8. PubMed ID: 21369644
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide does not modify the ability of cells in leprosy patients to incorporate [3H]-thymidine when incubated with M. leprae antigens.
Tadesse A; Taye E; Sandoval F; Shannon EJ
Lepr Rev; 2003 Sep; 74(3):206-14. PubMed ID: 14577465
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway and lower cytokine response.
Hernandez Mde O; Fulco Tde O; Pinheiro RO; Pereira Rde M; Redner P; Sarno EN; Lopes UG; Sampaio EP
Eur J Pharmacol; 2011 Nov; 670(1):272-9. PubMed ID: 21925494
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential.
Shannon EJ; Howe RC; McLean K; Hastings RC
Immunopharmacol Immunotoxicol; 1994 Nov; 16(4):717-29. PubMed ID: 7876469
[TBL] [Abstract][Full Text] [Related]
6. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
7. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
8. Activation of complement by Mycobacterium leprae requires disruption of the bacilli.
Lahiri R; Sandoval FG; Krahenbuhl JL; Shannon EJ
Lepr Rev; 2008 Sep; 79(3):311-4. PubMed ID: 19009980
[TBL] [Abstract][Full Text] [Related]
9. Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction.
Tadesse A; Abebe M; Bizuneh E; Mulugeta W; Aseffa A; Shannon EJ
Immunopharmacol Immunotoxicol; 2006; 28(3):431-41. PubMed ID: 16997792
[TBL] [Abstract][Full Text] [Related]
10. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.
Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN
Biomed Pharmacother; 2002 Feb; 56(1):13-9. PubMed ID: 11905505
[TBL] [Abstract][Full Text] [Related]
11. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
de Carsalade GY; Achirafi A; Flageul B
Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
[TBL] [Abstract][Full Text] [Related]
12. T cell-monocyte contact enhances tumor necrosis factor-alpha production in response to Mycobacterium leprae.
Sampaio EP; Oliveira RB; Warwick-Davies J; Neto RB; Griffin GE; Shattock RJ
J Infect Dis; 2000 Nov; 182(5):1463-72. PubMed ID: 11023469
[TBL] [Abstract][Full Text] [Related]
13. Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10.
Pacheco FS; Prata RBDS; Brandão SS; Ferreira H; Rodrigues TF; Brandão Dos Santos J; da Silva CO; Tavares IF; Mendes MA; Rodrigues ACDP; Machado AM; Nery JADC; Amadeu TP; Moraes MO; Sarno EN; Schmitz V
Immunohorizons; 2020 Feb; 4(2):47-56. PubMed ID: 32034084
[TBL] [Abstract][Full Text] [Related]
14. Differential handling of bacterial antigens in macrophages infected with Mycobacterium leprae as studied by immunogold labeling of ultrathin sections.
Rastogi N; Cadou S; Hellio R
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):278-91. PubMed ID: 2071985
[TBL] [Abstract][Full Text] [Related]
15. Antigenic protein from Mycobacterium leprae released in macrophages in vitro as indicator of viability of bacteria.
Nair I; Mahadevan PR
Int J Lepr Other Mycobact Dis; 1990 Sep; 58(3):540-7. PubMed ID: 2205688
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions.
Yamasaki PR; do Nascimento DC; Chelucci RC; de Faria Fernandes Belone A; Rosa PS; Diório SM; de Melo TR; Barbieri KP; Placeres MC; Carlos IZ; Chung MC; dos Santos JL
Bioorg Med Chem Lett; 2014 Jul; 24(14):3084-7. PubMed ID: 24907144
[TBL] [Abstract][Full Text] [Related]
17. Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction.
Moura DF; Teles RM; Ribeiro-Carvalho MM; Teles RB; Santos IM; Ferreira H; Fulco TO; Nery JA; Sampaio EP; Sarno EN
Br J Dermatol; 2007 Aug; 157(2):273-83. PubMed ID: 17553031
[TBL] [Abstract][Full Text] [Related]
18. Phagocytosis of Mycobacterium leprae by human monocyte-derived macrophages is mediated by complement receptors CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) and IFN-gamma activation inhibits complement receptor function and phagocytosis of this bacterium.
Schlesinger LS; Horwitz MA
J Immunol; 1991 Sep; 147(6):1983-94. PubMed ID: 1679838
[TBL] [Abstract][Full Text] [Related]
19. An in vitro model for the lepromatous leprosy granuloma: fate of Mycobacterium leprae from target macrophages after interaction with normal and activated effector macrophages.
Hagge DA; Ray NA; Krahenbuhl JL; Adams LB
J Immunol; 2004 Jun; 172(12):7771-9. PubMed ID: 15187161
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor production in patients with leprosy.
Barnes PF; Chatterjee D; Brennan PJ; Rea TH; Modlin RL
Infect Immun; 1992 Apr; 60(4):1441-6. PubMed ID: 1548069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
